130 related articles for article (PubMed ID: 3320577)
21. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
22. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien S; Cortes J; Koller CA; Giles FJ; Kornblau S; Andreeff M; Vey N; Pierce SR; Hayes K; Wong GC; Keating M; Kantarjian H
J Clin Oncol; 1999 Sep; 17(9):2819-30. PubMed ID: 10561358
[TBL] [Abstract][Full Text] [Related]
23. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
Greenberg BR; Durie BG; Barnett TC; Meyskens FL
Cancer Treat Rep; 1985 Dec; 69(12):1369-74. PubMed ID: 3865701
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes.
Hellström E; Robèrt KH; Gahrton G; Mellstedt H; Lindemalm C; Einhorn S; Björkholm M; Grimfors G; Udén AM; Samuelsson J
Eur J Haematol; 1988 May; 40(5):449-59. PubMed ID: 3378598
[TBL] [Abstract][Full Text] [Related]
25. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare.
Ohno R; Naoe T; Hirano M; Kobayashi M; Hirai H; Tubaki K; Oh H
Blood; 1993 Mar; 81(5):1152-4. PubMed ID: 8443376
[TBL] [Abstract][Full Text] [Related]
26. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
Bennett JM; Young MS; Liesveld JL; Paietta E; Miller KB; Lazarus HM; Marsh RD; Friedenberg WR; Saba HT; Hayes FA; Dewald GW; Hiddemann W; Rowe JM
Am J Hematol; 2001 Jan; 66(1):23-7. PubMed ID: 11426487
[TBL] [Abstract][Full Text] [Related]
28. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
[TBL] [Abstract][Full Text] [Related]
29. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C.
Letendre L; Noel P; White WL; Tefferi A; Litzow MR; Li CY; Schroeder G
Leuk Res; 1999 Sep; 23(9):811-5. PubMed ID: 10475620
[TBL] [Abstract][Full Text] [Related]
30. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes.
Harada M; Shibuya T; Teshima T; Murakawa M; Okamura T; Niho Y; Gondo H; Hayashi S; Akashi K; Tamura K
Leuk Res; 1993 Aug; 17(8):629-32. PubMed ID: 8355505
[TBL] [Abstract][Full Text] [Related]
32. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
33. Combined differentiating therapy for myelodysplastic syndromes: a phase II study.
Ferrero D; Bruno B; Pregno P; Stefani S; Larizza E; Ciravegna G; Luraschi A; Vietti-Ramus G; Schinco P; Bazzan M; Gallo E; Pileri A
Leuk Res; 1996 Oct; 20(10):867-76. PubMed ID: 8960111
[TBL] [Abstract][Full Text] [Related]
34. Low dose Ara-C for patients with myelodysplastic syndromes.
Powell BL; Capizzi RL; Jackson DV; Richards F; Muss HB; Lyerly ES; Rosenbaum DL; Connelly RA; Buss DH; Bearden JD
Leukemia; 1988 Mar; 2(3):153-6. PubMed ID: 3347093
[TBL] [Abstract][Full Text] [Related]
35. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
[TBL] [Abstract][Full Text] [Related]
36. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.
Koeffler HP; Heitjan D; Mertelsmann R; Kolitz JE; Schulman P; Itri L; Gunter P; Besa E
Blood; 1988 Mar; 71(3):703-8. PubMed ID: 3278754
[TBL] [Abstract][Full Text] [Related]
37. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
38. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
39. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Katayama N; Tanaka I; Minami N; Shirakawa S
Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
[TBL] [Abstract][Full Text] [Related]
40. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
Zwierzina H; Suciu S; Loeffler-Ragg J; Neuwirtova R; Fenaux P; Beksac M; Harousseau J; Nuessler V; Cermak J; Solbu G; Willemze R; de Witte T; Amadori S;
Leukemia; 2005 Nov; 19(11):1929-33. PubMed ID: 16151466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
